Literature DB >> 2944479

Comparative efficacy of ciprofloxacin and ceftriaxone in experimental arthritis caused by Escherichia coli.

A S Bayer, D C Norman, I K Blomquist.   

Abstract

Ciprofloxacin was compared with ceftriaxone in a rabbit model of septic arthritis caused by Escherichia coli. Both agents significantly reduced mean E. coli counts in septic joint fluid (P less than 0.0005 versus untreated controls) and also within infected synovial tissue (P less than 0.01 versus controls). Ciprofloxacin regimens caused a higher frequency (P less than 0.05) of synovial tissue sterilization (53%) than did ceftriaxone (25%).

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2944479      PMCID： PMC176463          DOI： 10.1128/AAC.30.1.184

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Sternoarticualr pyoarthrosis due to gram-negative bacilli. Report of eight cases.

Authors:  A S Bayer; A W Chow; J S Louie; L B Guze
Journal:  Arch Intern Med       Date:  1977-08

2.  Acidosis of synovial fluid correlates with synovial fluid leukocytosis.

Authors:  T T Ward; R T Steigbigel
Journal:  Am J Med       Date:  1978-06       Impact factor: 4.965

3.  Acute arthritis caused by gram-negative bacilli: a clinical characterization.

Authors:  D L Goldenberg; K D Brandt; E S Cathcart; A S Cohen
Journal:  Medicine (Baltimore)       Date:  1974-05       Impact factor: 1.889

4.  Experimental E. coli arthritis in the rabbit. A model of infectious and post-infectious inflammatory synovitis.

Authors:  D J Schurman; J Mirra; A Ding; D A Nagel
Journal:  J Rheumatol       Date:  1977       Impact factor: 4.666

5.  Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus.

Authors:  M A Sande; M L Johnson
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

6.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

7.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

8.  Efficacy of ciprofloxacin in experimental arthritis caused by Escherichia coli--in vitro-in vivo correlations.

Authors:  A S Bayer; D Norman; D Anderson
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

9.  Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks.

Authors:  A L Barry; R J Fass; J P Anhalt; H C Neu; C Thornsberry; R C Tilton; B G Painter; J A Washington
Journal:  J Clin Microbiol       Date:  1985-06       Impact factor: 5.948

10.  Studies on the pathophysiology and some host defense factors in staphylococcal arthritis in the rabbit and on the relationship of aseptic inflammation to infection rate.

Authors:  D A Nagel; J A Albright; J W Hollingsworth
Journal:  Yale J Biol Med       Date:  1966-10
View more
  2 in total

Review 1.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.